Since NSCLC patients undergoing EGFR-TKI therapy require long-term follow-up, non-contrast CT may be more appropriate due to its high cost-effectiveness, strong reproducibility and controllable adverse effects and complications. This evidence concerns the gene EGFR and non-small cell lung carcinoma.